|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC00511 |
Gene summary for LINC00511 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC00511 | Gene ID | 400619 |
| Gene name | long intergenic non-protein coding RNA 511 | |
| Gene Alias | LCAL5 | |
| Cytomap | 17q24.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 400619 | LINC00511 | CCI_1 | Human | Cervix | CC | 9.97e-53 | 2.99e+00 | 0.528 |
| 400619 | LINC00511 | CCI_2 | Human | Cervix | CC | 5.77e-34 | 2.66e+00 | 0.5249 |
| 400619 | LINC00511 | CCI_3 | Human | Cervix | CC | 9.02e-51 | 2.18e+00 | 0.516 |
| 400619 | LINC00511 | CCII_1 | Human | Cervix | CC | 1.91e-74 | 1.70e+00 | 0.3249 |
| 400619 | LINC00511 | Tumor | Human | Cervix | CC | 1.95e-07 | 2.01e-01 | 0.1241 |
| 400619 | LINC00511 | sample1 | Human | Cervix | CC | 2.17e-17 | 4.88e-01 | 0.0959 |
| 400619 | LINC00511 | sample3 | Human | Cervix | CC | 4.67e-35 | 4.79e-01 | 0.1387 |
| 400619 | LINC00511 | H2 | Human | Cervix | HSIL_HPV | 3.32e-13 | 2.82e-01 | 0.0632 |
| 400619 | LINC00511 | L1 | Human | Cervix | CC | 1.60e-05 | 2.88e-01 | 0.0802 |
| 400619 | LINC00511 | T1 | Human | Cervix | CC | 1.43e-27 | 5.22e-01 | 0.0918 |
| 400619 | LINC00511 | T2 | Human | Cervix | CC | 2.47e-06 | 3.27e-01 | 0.0709 |
| 400619 | LINC00511 | T3 | Human | Cervix | CC | 3.25e-30 | 4.72e-01 | 0.1389 |
| 400619 | LINC00511 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.72e-08 | 6.56e-01 | 0.0155 |
| 400619 | LINC00511 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.83e-07 | 7.82e-01 | -0.1808 |
| 400619 | LINC00511 | HTA11_2951_2000001011 | Human | Colorectum | AD | 4.19e-05 | 9.65e-01 | 0.0216 |
| 400619 | LINC00511 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.52e-17 | 1.29e+00 | -0.0811 |
| 400619 | LINC00511 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.78e-08 | 9.35e-01 | -0.1088 |
| 400619 | LINC00511 | HTA11_347_2000001011 | Human | Colorectum | AD | 3.97e-24 | 1.44e+00 | -0.1954 |
| 400619 | LINC00511 | HTA11_411_2000001011 | Human | Colorectum | SER | 3.23e-08 | 1.78e+00 | -0.2602 |
| 400619 | LINC00511 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.65e-09 | 1.24e+00 | -0.2196 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |